MedTech Terms
    The authoritative reference
    Back to De Novo & Breakthrough Pathways
    RegulatoryRegulated PathwaysQuality SystemGlobal MarketsPMA

    Premarket Approval

    FDA's most stringent device marketing application, required for high-risk Class III devices.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed September 19, 2026

    Definition

    Premarket Approval (PMA) is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices. PMA is the most stringent type of device marketing application required by the FDA. Unlike a 510(k), a PMA does not rely on comparison to a predicate. The sponsor must provide valid scientific evidence, usually including clinical investigation data, that gives reasonable assurance of safety and effectiveness. FDA may convene an advisory panel, inspects manufacturing facilities before approval, and later changes to an approved device often need a PMA supplement under 21 CFR 814.39.
    What the regulation says
    Section 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 360e), added by the Medical Device Amendments of 1976 (Pub. L. 94-295), enacted May 28, 1976, establishes the PMA framework. FDA implements this framework through 21 CFR Part 814. For Class III MedTech devices subject to PMA, applicants must provide valid scientific evidence giving reasonable assurance of safety and effectiveness for the proposed conditions of use. Unlike 510(k) clearance, PMA approval does not depend on substantial equivalence to a predicate. Under 21 CFR § 814.20, applications include nonclinical and clinical investigation results, device descriptions, manufacturing information, and proposed labeling. FDA reviews the evidence and manufacturing controls and may seek advisory panel input. Review can include manufacturing facility inspections. Approval may carry conditions under 21 CFR § 814.82, including post-approval studies where required. Under 21 CFR § 814.84, applicants must submit post-approval reports at FDA-specified intervals. Section 814.39 generally requires an approved PMA supplement before implementing changes affecting safety or effectiveness, subject to specified exceptions and alternative submission procedures. Not every device change requires the same submission, and post-approval studies are not universally required.

    What this means in practice

    PMA submissions must include valid scientific evidence, typically from adequate and well-controlled clinical investigations, that the device is safe and effective for its intended use. They also undergo a Pre-Approval Inspection (PAI) of the manufacturing facility. Post-approval, PMA devices remain subject to conditions of approval, post-approval studies, and annual reports.

    Examples

    • An implantable cardiac defibrillator approved via original PMA supported by a pivotal randomized trial.
    • A new indication for an existing PMA device pursued through a PMA Supplement rather than a new original PMA.

    Use cases

    1 scenario
    1

    Novel implantable neurostimulator

    Clinical & RA team

    An implantable device for treatment-resistant depression has no predicate. The sponsor runs an IDE-authorized pivotal trial, then submits a PMA with full clinical, manufacturing, and biocompatibility data, plus a cybersecurity plan for the patient programmer.

    OutcomeAfter a panel meeting and inspection, FDA grants PMA approval with post-approval study commitments.
    Common pitfalls
    • •Assuming a 510(k) pathway will work for novel high-risk devices. Class III devices default to PMA unless reclassified.
    • •Underestimating the manufacturing inspection component (PAI); GMP nonconformities can delay approval regardless of clinical data quality.
    • •Building a clinical program without an early FDA Pre-Submission (Q-Sub) meeting to align on endpoints, control, and statistical plan.
    • •Confusing PMA approval with 510(k) clearance in labeling and marketing materials.

    Frequently asked questions

    510(k) results in clearance based on substantial equivalence to a predicate device and is used for most Class II devices. PMA results in approval based on independent evidence of safety and effectiveness (usually clinical trials) and is required for Class III devices without a suitable predicate.

    Cross-references

    Governed by

    Uses

    Often confused with

    See also

    Related terms

    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Learning paths (2)
    Comparisons (1)

    Latest in MedTech

    Sources

    3 sources

    Every citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

    Tier 1Binding law and standards· 1Tier 2Regulator guidance and consensus· 2
    Link health: 2 verified 1 unchecked· last checked 2026-06-20
    FDA·2eCFR·1
    1. 1
      Premarket Approval (PMA)
      Tier 2 Verified
      FDAfda.gov
    2. 2
      21 CFR Part 814
      Tier 1 Verified
      eCFRecfr.gov
    3. 3
      PMA Application Contents
      Tier 2 Unchecked
      FDAfda.gov

    Inline markers like [1] jump to the matching reference above.